News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Oral HRS-7535 shows promise in glycaemic control for T2D patients
16 Oct 2026
byStephen Padilla
Use of the once-daily oral HRS-7535, an investigational small-molecule GLP-1 receptor agonist (RA) for type 2 diabetes (T2D) and weight management, demonstrates noninferiority to dapagliflozin for glycated haemoglobin (HbA1c) reduction in Chinese adults with T2D, results of the OUTSTAND-2 phase III trial have shown. Treatment differences are also in favour of HRS-7535, with superiority at the 90-mg dose.
16 Oct 2026







